Logo Image
Opinion|Videos|May 12, 2025

Applying Trial Data to Real-World Practice in ALK+ NSCLC

Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these collective data have changed perspectives on frontline therapies for ALK+ non–small cell lung cancer (NSCLC).

Episodes in this series

Real-World Settings and Evolution of Frontline Therapy

Key Themes:

  • Comparison of clinical trial outcomes to real-world patient experiences
  • Impact of clinical data (ALINA, CROWN, eXalt3) on frontline therapy choices
  • Evolving perspective on frontline therapies for ALK+ NSCLC

Notable Insights:

  • Grizzard addressed how well outcomes from trials like CROWN and eXalt3 reflect real-world patient experiences

Dr Dietrich summarized how recent clinical data has changed the landscape of frontline therapies for ALK+ NSCLC

Related Content